PDS Biotechnology Corp Files 8-K
Ticker: PDSB · Form: 8-K · Filed: Aug 5, 2024 · CIK: 1472091
| Field | Detail |
|---|---|
| Company | Pds Biotechnology Corp (PDSB) |
| Form Type | 8-K |
| Filed Date | Aug 5, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.00033 |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, 8-k, corporate-update
TL;DR
PDS Biotech filed an 8-K on Aug 5th, likely routine updates.
AI Summary
On August 5, 2024, PDS Biotechnology Corporation filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits." No specific financial figures or new material events were detailed in the provided excerpt, but it confirms the filing date and company information.
Why It Matters
This filing indicates PDS Biotechnology Corp is providing updates or disclosures to the SEC, which could contain important information for investors regarding the company's status or financial health.
Risk Assessment
Risk Level: low — The provided excerpt is a standard SEC filing notification and does not contain specific material events or financial data that would indicate a change in risk.
Key Numbers
- 001-37568 — SEC File Number (Identifies the company's filing history with the SEC.)
- 26-4231384 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- PDS Biotechnology Corp (company) — Registrant
- August 5, 2024 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- 303A College Road East, Princeton, NJ 08540 (address) — Principal Executive Offices
- Edge Therapeutics, Inc. (company) — Former Company Name
FAQ
What specific "Other Events" are being reported by PDS Biotechnology Corp on August 5, 2024?
The provided excerpt does not detail the specific "Other Events" being reported; it only lists the category of the filing.
What "Financial Statements and Exhibits" are included in this 8-K filing?
The excerpt does not specify the content of the "Financial Statements and Exhibits" but confirms their inclusion in the filing.
What was PDS Biotechnology Corp's former name?
PDS Biotechnology Corporation's former name was Edge Therapeutics, Inc.
When did the company change its name from Edge Therapeutics, Inc.?
The date of the name change from Edge Therapeutics, Inc. was September 11, 2009.
What is the principal executive office address for PDS Biotechnology Corp?
The principal executive office address is 303A College Road East, Princeton, NJ 08540.
Filing Stats: 484 words · 2 min read · ~2 pages · Grade level 11.4 · Accepted 2024-08-05 08:00:23
Key Financial Figures
- $0.00033 — h registered Common Stock, par value $0.00033 per share PDSB The Nasdaq Capital M
Filing Documents
- ef20033543_8k.htm (8-K) — 28KB
- ef20033543_ex99-1.htm (EX-99.1) — 14KB
- image00001.jpg (GRAPHIC) — 3KB
- 0001140361-24-035618.txt ( ) — 184KB
- pdsb-20240805.xsd (EX-101.SCH) — 4KB
- pdsb-20240805_lab.xml (EX-101.LAB) — 21KB
- pdsb-20240805_pre.xml (EX-101.PRE) — 16KB
- ef20033543_8k_htm.xml (XML) — 4KB
01
Item 8.01 Other Events. On August 5, 2024, PDS Biotechnology Corporation issued a press release announcing that an abstract presenting updated data from the VERSATILE-002 trial evaluating first-line treatment with Versamune HPV (formerly PDS0101) in combination with KEYTRUDA (pembrolizumab) in patients with HPV16-positive recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) has been accepted for presentation at the European Society for Medical Oncology (ESMO) Congress 2024 being held September 13-17, 2024, in Barcelona, Spain. A copy of the press release is filed herewith as Exhibit 99.1 and incorporated by reference herein.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 99.1 Press Release Dated August 5, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL Document) Signature Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PDS BIOTECHNOLOGY CORPORATION Date: August 5, 2024 By: /s/ Frank Bedu-Addo, Ph.D. Name: Frank Bedu-Addo, Ph.D. Title: President and Chief Executive Officer